Subramaniam D

No ORCID on file · 2 papers in corpus

2024

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.

BMJ open ·doi:10.1136/bmjopen-2024-087431

ObjectivePregnant women with COVID-19 are at elevated risk for severe outcomes, but clinical data on management of these patients are limited. Monoclonal antibodies, such as casirivimab plus imdevimab (CAS+IMD), have proven effective in tre…

2016

Bitter melon: a panacea for inflammation and cancer.

Chinese journal of natural medicines ·doi:10.1016/s1875-5364(16)60002-x

Nature is a rich source of medicinal plants and their products that are useful for treatment of various diseases and disorders. Momordica charantia, commonly known as bitter melon or bitter gourd, is one of such plants known for its biologi…